Last reviewed · How we verify

ATRA+Chemo — Competitive Intelligence Brief

ATRA+Chemo (ATRA+Chemo) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Retinoid + chemotherapy combination. Area: Oncology.

marketed Retinoid + chemotherapy combination Retinoic acid receptor (RAR) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ATRA+Chemo (ATRA+Chemo) — Shanghai Jiao Tong University School of Medicine. ATRA (all-trans retinoic acid) combined with chemotherapy induces differentiation of leukemic blasts and enhances chemotherapy cytotoxicity in acute promyelocytic leukemia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ATRA+Chemo TARGET ATRA+Chemo Shanghai Jiao Tong University School of Medicine marketed Retinoid + chemotherapy combination Retinoic acid receptor (RAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Retinoid + chemotherapy combination class)

  1. Shanghai Jiao Tong University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ATRA+Chemo — Competitive Intelligence Brief. https://druglandscape.com/ci/atra-chemo. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: